Want to see AU:RHT full AI Analyst Report?
RHT Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.06
Previous CloseN/A
Volume166.47K
Average Volume (3M)274.25K
Market Cap
AU$27.67M
Enterprise ValueAU$23.50M
Total Cash (Recent Filing)AU$2.69M
Total Debt (Recent Filing)AU$5.20M
Price to Earnings (P/E)40.0
Beta1.85
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding477,120,240
10 Day Avg. Volume456,299
30 Day Avg. Volume274,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.89
Price to Sales (P/S)1.60
P/FCF Ratio22.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring, Diversified Revenue ModelResonance Health’s mix of subscription/licensing, per-scan usage fees and bespoke clinical-trial services creates multiple durable revenue streams. This reduces single-customer risk, supports predictable recurring income and enables long-term contracts and upsell opportunities to healthcare and pharma clients.
Stable Balance Sheet With Moderate LeverageModerate leverage and a >50% equity ratio provide financial flexibility to fund product development and partnerships without excessive refinancing risk. A stable capital structure helps weather industry cadence and supports multi-period investment in AI and imaging platform integration.
Consistent Gross Margins And Positive Operating Cash FlowSteady gross margins and positive operating cash flow show the core imaging business converts revenues to cash at the operational level. That durability underpins reinvestment in product R&D and commercialisation, even if free cash flow is temporarily pressured by investing or working-capital timing.
Bears Say
Negative Profitability MarginsPersistent negative EBIT and net margins indicate the business has yet to achieve sustainable operating profitability. Over months this constrains reinvestment, increases reliance on external financing or dilution, and signals structural gaps between revenue scale and fixed cost base.
Sharp Decline In Free Cash FlowA 66% fall in free cash flow is a structural concern: it reduces internal funding for growth and increases sensitivity to funding markets. If persistent, it can force capital-raising, delay product rollouts, or constrain clinical trial service capacity that underpins long-term contracts.
Negative Return On EquityNegative ROE reflects returns inadequate relative to capital employed and signals inefficient use of shareholder equity. Over a multi-month horizon this undermines investor confidence, complicates access to growth capital and highlights deeper profitability or scaling issues in the core business.
Resonance Health Ltd News
RHT FAQ
What was Resonance Health Ltd’s price range in the past 12 months?
Resonance Health Ltd lowest share price was AU$0.03 and its highest was AU$0.06 in the past 12 months.
What is Resonance Health Ltd’s market cap?
Resonance Health Ltd’s market cap is AU$27.67M.
When is Resonance Health Ltd’s upcoming earnings report date?
Resonance Health Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 27 days.
How were Resonance Health Ltd’s earnings last quarter?
Resonance Health Ltd released its earnings results on Feb 26, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Resonance Health Ltd overvalued?
According to Wall Street analysts Resonance Health Ltd’s price is currently Overvalued.
Does Resonance Health Ltd pay dividends?
Resonance Health Ltd does not currently pay dividends.
What is Resonance Health Ltd’s EPS estimate?
Resonance Health Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resonance Health Ltd have?
Resonance Health Ltd has 477,120,240 shares outstanding.
What happened to Resonance Health Ltd’s price movement after its last earnings report?
Resonance Health Ltd reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Resonance Health Ltd?
Currently, no hedge funds are holding shares in AU:RHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resonance Health Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RHT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$77.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.14%
Trailing 12-Months
Company Description
Resonance Health Ltd
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Middle East, and Africa. Its portfolio of non-invasive, MRI-based diagnostic tools includes FerriScan, a system for quantifying liver iron concentration (LIC); FerriSmart, leveraging artificial intelligence (AI) for automated, real-time assessment of LIC; HepaFat-AI, an AI-driven solution for real-time, multi-metric liver fat quantification; CardiacT2, which provides dual analysis in conjunction with FerriScan to evaluate cardiac iron accumulation; HepaFat-Scan, a non-invasive MRI method for assessing liver fat within tissue; and LiverSmart, a comprehensive non-invasive MRI device integrating FerriSmart and HepaFat-AI for a unified report. The company further extends its offerings to include quantitative imaging measurements and Contract Research Organization (CRO) services, encompassing rigorous image analysis, imaging charter development, robust project and data management, proactive issue resolution, site tracking with clinical trial progress reports, and streamlined data flow coordination. They also provide comprehensive biomarker services, covering analysis of blood, urine, and protein analytes, alongside RNA, DNA, and genotyping. Their support for multinational and multicenter clinical trials extends to protocol development, subject inclusion/exclusion criteria assessment, dose modification strategies, new therapy safety profile evaluations, and establishing primary and secondary endpoints for drug efficacy. Additionally, they supply phantoms crucial for MRI machine calibration. Its client base includes clinicians, who utilize their solutions for managing human diseases, and pharmaceutical and therapeutic companies engaged in clinical research. Established in 1987, Resonance Health Limited maintains its headquarters in Burswood, Australia.
Technical Analysis
Pro Medicus Limited
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
Artrya Limited
―